Bausch & Lomb Pharma Holdings Corp.

Bausch-lomb Incorporated

Senju Pharmaceutical Co., Ltd.

Mitsubishi Tanabe Pharma Corporation

Ista Pharmaceuticals, Inc.

George Baklayan

Angel Padilla

Shirou Sawa

Shuhei Fujita

Angeliqueo E Padilla

Novel compositions including bepotastine besilate and a corticosteroid are provided, compositions including at least about 0.008% w/v benzalkonium chloride, and compositions including hydroxypropylmethyl cellulose E15 LV.

Bepotastine compositions

Formulations and methods that provided enhanced bromfenac penetration into ocular tissue when topically administered, compared to the currently available BROMDAY&#x2122; formulation and method when topically administered. The formulations and methods did so while retaining the patient convenience of a once-daily administration and advantageously lowered the bromfenac concentration dosed to the patient.

Bromfenac bioavailability

An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. An embodiment of said liquid preparation does not include any preservative. Said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).

Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid

Growing community of inventors

Huntington Beach, CA, United States of America

George Baklayan